the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer

Immunotherapy Clinical Trial

Official title: An Exploratory Analysis of the Predictive Value of Immune Cell Using Single-cell Sequencing on the Outcome of Locally Advanced Cervical Cancer Treated by Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor

Status Recruiting

Clinical Trial Summary

To explore the predictive value of immune cells by single-cell sequencing on the outcome of locally advanced cervical cancer treated by concurrent chemoradiotherapy Followed by PD-1 inhibitor

Clinical Trial Description

Concurrent chemoradiotherapy is the standard treatment for patients with locally advanced cervical cancer, but the treatment failure rate is up to 40% in previous studies. Immunotherapy using PD-1 inhibitor showed an objective response rate of 12-50% in studies, and pembrolizumab was approved by the US Food and Drug Administration for patients with advanced PD-L1-positive cervical cancer who experienced progression during or after chemotherapy. And according to KEYNOTE-A18, the addition of PD-1 inhibitor Pembrolizumab to the current concurrent chemoradiotherapy improved the PFS of such group of patients. But the detailed change of immune cells (tumor microenvironment and PBMC) during treatment is unknown, and studies on the relationship between immune cells and treatment-related side effect and efficiency is also in need. ;

Related Conditions & MeSH terms

• Concurrent Chemoradiotherapy
• Immunotherapy
• Locally Advanced Cervical Carcinoma
• Uterine Cervical Neoplasms

• NCT number: NCT06378840
• Study type: Observational
• Source: RenJi Hospital
• Contact: Yongrui Bai, Dr.
• Phone: 86-2-68383459
• Email: baiyongrui@renji.com
• Status: Recruiting
• Start date: January 1, 2022
• Completion date: December 30, 2024